查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年单克隆抗体市场预测 - 按来源类型、生产类型、适应症、途径、分销渠道、用途、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1339962

到 2030 年单克隆抗体市场预测 - 按来源类型、生产类型、适应症、途径、分销渠道、用途、最终用户和地区进行的全球分析

Monoclonal Antibodies Market Forecasts to 2030 - Global Analysis By Source Type, Production Type, Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球单克隆抗体市场规模为2306亿美元，预计到2030年将达到5915亿美元，预测期内年复合成长率为14.4%。

单克隆抗体 (mAb) 是一种能够与特定细胞类型结合的蛋白质。这些是相同的免疫球蛋白，可识别抗原上的特定结合位点，并由单个 B 细胞产生。由于单克隆抗体对不同表位具有选择性，因此它们越来越多地用于各种疾病的治疗和诊断。单克隆抗体目前广泛用于治疗多种疾病，包括癌症、心血管疾病、自身免疫性疾病、血液疾病和感染疾病等。

据世界卫生组织 (WHO) 称，2020 年全球约有 1000 万人将死于癌症。这相当于每年所有癌症死亡人数的三分之一。

市场动态：

促进因素

  • 对个人化医疗的青睐日益增长。
  • 治疗性抗体的研究和开发正在为标靶治疗铺平道路，并增加对个人化医疗的需求。由于单克隆抗体用于治疗癌症，因此与传统化疗相比，这些治疗方法不太可能引起副作用。个体化癌症治疗和单克隆抗体减少副作用预计将促进新兴市场的开拓。

抑制要素

  • 严重的法规问题。
  • 有关药物审批和药物测试的严格法规要求阻碍了市场扩张。此外，许多国家禁止在获得必要的批准之前对药物进行人体测试。曾经无法治癒的疾病现在可以通过商业治疗方法治愈，这为创新药物引入市场铺平了道路。与这些药物相关的众多法规合规性阻碍了市场扩张。

机会：

  • 癌症罹患率增加
  • 影响市场增长率的主要要素之一是癌症罹患率的上升。随着单克隆抗体的全球市场迅速扩大，发达国家越来越多地使用单克隆抗体来治疗多种肿瘤。罕见疾病和慢性感染疾病的患病率迅速增加，以及大量单克隆抗体被推荐用于癌症治疗方案，为收入扩张提供了市场潜力。

威胁

  • 单克隆抗体高成本。
  • 由于单克隆抗体的生产成本昂贵，因此仅在发达国家使用，而在新兴国家或较贫穷国家不使用。高昂的药品成本可能会阻碍贫穷国家许多患者群体的吸收并限制他们获得药品。高开发成本和随后的价格上涨可能会限制市场扩张。

新冠肺炎 (COVID-19) 影响：

  • 此次疫情对经济产生了三个主要影响。它直接影响了药品的需求和生产，扰乱了分配系统，并对企业和金融市场产生了财务影响。单克隆抗体市场受益于这一影响，因为单克隆抗体可以预防和治疗早期感染疾病。许多公司正在使用单克隆抗体来开发针对新型冠状病毒的有效疫苗。研究人员通过危机识别得到了政府机构的支持。
  • 肿瘤学领域预计在预测期内规模最大
  • 由于癌症患病率不断上升，预计癌症行业在预测期内将达到最高水平。这种扩张是由于治疗各种癌症时对单克隆抗体的需求不断增加。癌症患者对单克隆抗体需求量大的主要原因之一是其在癌症治疗中的有效性提高，且副作用极小或无副作用。
  • 医院药房业务预计在预测期内年复合成长率最高
  • 预计医院药房行业在预测期内的年复合成长率最高。这是由于癌症、类风湿性关节炎等许多慢性疾病的患病率上升导致住院患者人数增加。由于现代医疗保健服务的普及，酒店药房市场收入正在增加。这些药店出售各种产品和药品，可以轻鬆购买各种药品。

占比最大的地区

由于主要企业的存在和大量的产品核可，预计北美在预测期内将占据最大的市场份额。该地区对单克隆抗体的需求是由于人们对有效疾病治疗产品的接受度不断提高而推动的。此外，公司研发支出的增加和政府对癌症研究的资助正在推动创新单克隆抗体治疗的发展。

复合年复合成长率最高的地区：

由于可支配收入的增加和对医疗保健的兴趣日益浓厚，预计亚太地区在预测期内将保持最高的年复合成长率。预计人口中癌症和其他慢性病患病率增加的主要原因是加工食品消费量增加、吸烟率增加和烟草使用增加。此外，不断增长的老年人口可能会对不久的将来的销售产生积极影响。

免费定制服务：

订阅此报告的客户将收到以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（注：基于可行性检查）
  • 竞争标杆管理
    • 根据产品系列、地域分布和战略联盟对主要企业进行基准测试

目录

第1章执行摘要

第2章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 资料挖掘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 假设

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 用途分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球单克隆抗体市场：按来源类型

  • 人性化
  • 奇美拉
  • 小鼠或大鼠
  • 男人
  • 其他产地类型

第6章全球单克隆抗体市场：按生产类型

  • In Vitro
  • In Vivo

第7章全球单克隆抗体市场：按适应症分类

  • 感染疾病
  • 炎症性疾病
  • 癌症
    • 肺癌
    • 结直肠癌
    • 卵巢癌
    • 乳腺癌
  • 自身免疫性疾病
  • 其他适应症

第8章全球单克隆抗体市场：按给药途径

  • 玻璃体内
  • 皮下的
  • 静脉

第9章全球单克隆抗体市场：按分销渠道划分

  • 网上药房
  • 医院药房
  • 零售药房

第10章全球单克隆抗体市场：按用途

  • 感染疾病
  • 神经系统疾病
  • 自身免疫性疾病
  • 肿瘤学
  • 其他用途

第11章全球单克隆抗体市场：按最终用户分类

  • 专业中心
  • 医院
  • 调查机构
  • 其他最终用户

第12章全球单克隆抗体市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第13章进展

  • 合同、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第14章公司简介

  • Johnson & Johnson Services, Inc.
  • Viatris Inc.
  • Abbott Laboratories
  • Eli Lilly And Company
  • Bristol-Myers Squibb
  • Biogen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Novartis AG
  • Thermo Fisher Scientific, Inc.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi SA
  • Merck & Co., Inc.
  • Amgen Inc.
  • Bayer AG
  • Lonza Group
Product Code: SMRC23669

According to Stratistics MRC, the Global Monoclonal Antibodies Market is accounted for $230.6 billion in 2023 and is expected to reach $591.5 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Monoclonal antibodies (mAbs) are a class of proteins with the capacity to attach to particular cell types. These are identical immunoglobulins that recognise a specific binding site on the antigen and were produced by a single B-cell. MAbs are being utilised more frequently for therapeutic and diagnostic purposes for various diseases because of their selectivity to distinct epitopes. Monoclonal antibodies are now widely used to treat a variety of conditions, including cancer, cardiovascular illness, autoimmune disorders, blood disorders, and infectious diseases.

According to the World Health Organization, in 2020, around 10 million people died due to cancer worldwide. This has proportionated one third deaths due to cancer in respective year.

Market Dynamics:

Driver:

  • Favourability for personalised medicine has increased.
  • The desire for personalised medicine is increasing as research and development of therapeutic antibodies has paved the way for targeted therapies because different people respond and behave differently to a given medication. Since monoclonal antibodies are used in cancer therapy, these treatments are less likely to cause adverse effects than traditional chemotherapy. The development of the market is anticipated to be aided by personalised cancer therapy and fewer adverse effects from monoclonal antibodies.

Restraint:

  • Stringent regulatory issues.
  • The market's expansion is hindered by strict regulatory requirements pertaining to drug approvals and drug testing. Additionally, a number of nations prohibit the testing of medicines on people before they have received the required authorisation. The ability of commercially available treatments to cure once-incurable diseases has paved the path for the introduction of ground-breaking drugs to the market. The market's expansion is hampered by the numerous regulatory compliances that are associated with these medications.

Opportunity:

  • Increase in the incidence of cancer.
  • One of the main factors influencing the market's growth rate is the rising incidence of cancer. Due to the rapidly expanding global market for monoclonal antibodies, monoclonal antibodies are increasingly being employed in the treatment of numerous tumours in industrialised nations. Rapid increases in the prevalence of rare and chronic infectious diseases, as well as the large number of monoclonal antibodies recommended for use in cancer treatment regimens, have provided the market with potential for revenue growth.

Threat:

  • High cost associated with monoclonal antibodies.
  • Monoclonal antibodies are still only employed in industrialised nations and not in emerging or poor nations due to the high cost of production. Such high drug costs can impede uptake and restrict access to medicines for sizable patient populations in poor nations. The high expenditures of the development and the subsequent price increase may limit market expansion.

COVID-19 Impact:

  • The pandemic had three main effects on the economy: it directly influenced drug demand and production, it disrupted distribution systems, and it had a financial impact on businesses and financial markets. The market for monoclonal antibodies has benefited from the impact since these antibodies work to prevent and treat early infections. Monoclonal antibodies are being used by numerous businesses in an effort to develop an effective vaccine for a novel corona virus disease. The researchers are assisted by government agencies by their approval of crises.
  • The cancer segment is expected to be the largest during the forecast period
  • The cancer segment is expected to be the largest during the forecast period, owing to increased prevalence of cancer. This expansion is simply ascribed to the increased demand for monoclonal antibodies in the treatment of various cancers. One of the main reasons why there is such a large demand for monoclonal antibodies among cancer patients is their increased effectiveness in the treatment of cancer with minimal or no adverse effects.
  • The hospital pharmacy segment is expected to have the highest CAGR during the forecast period
  • The hospital pharmacy segment is expected to have the highest CAGR during the forecast period. This is due to a rise in hospital admissions brought on by the rising prevalence of a number of chronic diseases like cancer, autoimmune disorders, and rheumatoid arthritis. The market income of hospital pharmacy has increased as a result of greater access to modern healthcare services. These pharmacies are an easy way to purchase a variety of medications due to the large variety of products and drugs they carry.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, owing to the strong presence of key business players and number of product approvals. Demand for monoclonal antibodies in the local market is driven by increased product acceptance for efficient disease treatment. In addition, rising R&D spending by businesses and government funding for cancer research have facilitated the development of innovative monoclonal antibody treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the increasing disposable income and rising focus on healthcare. The main causes that are anticipated to increase the prevalence of cancer and other chronic diseases in the population are the rising consumption of processed foods, rising smoking rates, and rising tobacco use. Additionally, the growing elderly population will have a favourable effect on sales in the near future.

Key players in the market:

Some of the key players in Monoclonal Antibodies market include: Johnson & Johnson Services, Inc., Viatris Inc., Abbott Laboratories, Eli Lilly And Company, Bristol-Myers Squibb, Biogen Inc., Merck & Co., Inc., Pfizer Inc, Novartis AG, Thermo Fisher Scientific, Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG and Lonza Group.

Key Developments:

  • In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
  • In February 2022, Bebtelovimab is an antibody that can reduce the effects of Omicron variant. Eli Lilly and Company announced that the Food and Drug Administration (FDA) of the United States had given bebtelovimab an Emergency Use Authorization (EUA).
  • In January 2022, Lonza and HaemaLogiX Ltd. (HaemaLogiX) made a deal for Lonza to make the next clinical batch (cGMP) of KappaMab, HaemaLogiX's most important treatment candidate for multiple myeloma.

Source types Covered:

  • Humanized
  • Chimeric
  • Murine
  • Human
  • Other Source Types

Production Types Covered:

  • In Vitro
  • In Vivo

Route of Administration Covered:

  • Intravitreal
  • Subcutaneous
  • Intravenous

Distribution Channels Covered:

  • Navy
  • Airforce
  • Army
  • Other End Users

Applications Covered:

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Specialty Centers
  • Hospitals
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Monoclonal Antibodies Market, By Source Type

  • 5.1 Introduction
  • 5.2 Humanized
  • 5.3 Chimeric
  • 5.4 Murine
  • 5.5 Human
  • 5.6 Other Source Types

6 Global Monoclonal Antibodies Market, By Production Type

  • 6.1 Introduction
  • 6.2 In Vitro
  • 6.3 In Vivo

7 Global Monoclonal Antibodies Market, By Indication

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Inflammatory Diseases
  • 7.4 Cancer
    • 7.4.1 Lung cancer
    • 7.4.2 Colorectal cancer
    • 7.4.3 Ovarian cancer
    • 7.4.4 Breast cancer
  • 7.5 Autoimmune Diseases
  • 7.6 Other Indications

8 Global Monoclonal Antibodies Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intravitreal
  • 8.3 Subcutaneous
  • 8.4 Intravenous

9 Global Monoclonal Antibodies Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Hospital Pharmacy
  • 9.4 Retail Pharmacy

10 Global Monoclonal Antibodies Market, By Application

  • 10.1 Introduction
  • 10.2 Infectious Diseases
  • 10.3 Neurological Diseases
  • 10.4 Autoimmune Diseases
  • 10.5 Oncology
  • 10.6 Other Applications

11 Global Monoclonal Antibodies Market, By End User

  • 11.1 Introduction
  • 11.2 Specialty Centers
  • 11.3 Hospitals
  • 11.4 Research Institutes
  • 11.5 Other End Users

12 Global Monoclonal Antibodies Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Johnson & Johnson Services, Inc.
  • 14.2 Viatris Inc.
  • 14.3 Abbott Laboratories
  • 14.4 Eli Lilly And Company
  • 14.5 Bristol-Myers Squibb
  • 14.6 Biogen Inc.
  • 14.7 Merck & Co., Inc.
  • 14.8 Pfizer Inc
  • 14.9 Novartis AG
  • 14.10 Thermo Fisher Scientific, Inc.
  • 14.11 AstraZeneca plc
  • 14.12 GlaxoSmithKline plc
  • 14.13 Novo Nordisk A/S
  • 14.14 Sanofi S.A.
  • 14.15 Merck & Co., Inc.
  • 14.16 Amgen Inc.
  • 14.17 Bayer AG
  • 14.18 Lonza Group

List of Tables

  • Table 1 Global Monoclonal Antibodies Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Monoclonal Antibodies Market Outlook, By Source Type (2021-2030) ($MN)
  • Table 3 Global Monoclonal Antibodies Market Outlook, By Humanized (2021-2030) ($MN)
  • Table 4 Global Monoclonal Antibodies Market Outlook, By Chimeric (2021-2030) ($MN)
  • Table 5 Global Monoclonal Antibodies Market Outlook, By Murine (2021-2030) ($MN)
  • Table 6 Global Monoclonal Antibodies Market Outlook, By Human (2021-2030) ($MN)
  • Table 7 Global Monoclonal Antibodies Market Outlook, By Other Source Types (2021-2030) ($MN)
  • Table 8 Global Monoclonal Antibodies Market Outlook, By Production Type (2021-2030) ($MN)
  • Table 9 Global Monoclonal Antibodies Market Outlook, By In Vitro (2021-2030) ($MN)
  • Table 10 Global Monoclonal Antibodies Market Outlook, By In Vivo (2021-2030) ($MN)
  • Table 11 Global Monoclonal Antibodies Market Outlook, By Indication (2021-2030) ($MN)
  • Table 12 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 13 Global Monoclonal Antibodies Market Outlook, By Inflammatory Diseases (2021-2030) ($MN)
  • Table 14 Global Monoclonal Antibodies Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 15 Global Monoclonal Antibodies Market Outlook, By Lung cancer (2021-2030) ($MN)
  • Table 16 Global Monoclonal Antibodies Market Outlook, By Colorectal cancer (2021-2030) ($MN)
  • Table 17 Global Monoclonal Antibodies Market Outlook, By Ovarian cancer (2021-2030) ($MN)
  • Table 18 Global Monoclonal Antibodies Market Outlook, By Breast cancer (2021-2030) ($MN)
  • Table 19 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 20 Global Monoclonal Antibodies Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 21 Global Monoclonal Antibodies Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 22 Global Monoclonal Antibodies Market Outlook, By Intravitreal (2021-2030) ($MN)
  • Table 23 Global Monoclonal Antibodies Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 24 Global Monoclonal Antibodies Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 25 Global Monoclonal Antibodies Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Monoclonal Antibodies Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Monoclonal Antibodies Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 28 Global Monoclonal Antibodies Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 Global Monoclonal Antibodies Market Outlook, By Application (2021-2030) ($MN)
  • Table 30 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 31 Global Monoclonal Antibodies Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 32 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 33 Global Monoclonal Antibodies Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 34 Global Monoclonal Antibodies Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 35 Global Monoclonal Antibodies Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Monoclonal Antibodies Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 37 Global Monoclonal Antibodies Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Monoclonal Antibodies Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 39 Global Monoclonal Antibodies Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.